Avicanna Inc. has rooted itself as an innovative biotechnology
company in the medical cannabis space.

Our headquarters is located within JLABS @ Toronto (Canada) as the first and only cannabinoid-related company to be integrated into the Johnson & Johnson Incubation Center in Toronto.

At Avicanna, we are focused on biotechnology, product development and research.  Our team develops our cannabinoid-based products within our state-of-the-art CGMP facilities in-line with Health Canada standards, and works closely with several of the top Canadian medical institutions, including scientists from the University Health Network (UHN), Princess Margaret Cancer Centre and Toronto General Hospital. We believe that Canada has set the gold standard in the global medical cannabis industry and that we are well positioned to be a leader for innovation and best practices.

Currently, our major product line is PURA Elements, produced with natural plant extracts and botanicals.  This line includes one of the first transdermal cannabinoid patches worldwide (see Products & Services for more info).

Our company is expanding our multinational approach, which includes our current presence in Canada, USA, Argentina, Colombia and several other emerging medical cannabis markets. Additionally, Avicanna is active in the education of patients and doctors regarding medical cannabis within Canada.

Above all, at Avicanna we aim to provide cannabinoid-based therapies that are both federally approved and medically tested.  As our company continues to grow in all facets of this booming industry, we are excited to bring novel updates as we move forward.